The content on this site is intended for healthcare professionals only

Breast

Prostate & urology

Lung & pleura

Colorectal & gastro

Melanoma & skin

Head & neck

Ovary & gynaecology

+ -

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

2017 ASCO Annual Meeting

2 - 6 Jun 2017

McCormick Place, Chicago, United States of America

Low-value practices in oncology contributing to financial toxicity

Dr Bishal Gyawali - Nagoya University, Nagoya, Japan

Low-value practices in oncology contributing to financial toxicity ( Dr Bishal Gyawali - Nagoya University, Nagoya, Japan )

The past and future of breast cancer treatment—from the papyrus to individualise...

Dr Felipe Ades - Hospital Israelita Albert Einstein, Morumbi, São Paulo

The past and future of breast cancer treatment—from the papyrus to individualised treatment approaches ( Dr Felipe Ades - Hospital Israelita Albert Einstein, Morumbi, São Paulo )

(1/6) ASCO 2017: Introduction to Expert discussion on the latest in prostate can...

Dr Neal Shore, Prof Karim Fizazi, Prof Kurt Miller and Prof Nicholas James

(1/6) ASCO 2017: Introduction to Expert discussion on the latest in prostate cancer ( Dr Neal Shore, Prof Karim Fizazi, Prof Kurt Miller and Prof Nicholas James )

(2/6) ASCO 2017: LATITUDE data

Dr Neal Shore, Prof Karim Fizazi, Prof Kurt Miller and Prof Nicholas James

(2/6) ASCO 2017: LATITUDE data ( Dr Neal Shore, Prof Karim Fizazi, Prof Kurt Miller and Prof Nicholas James )

(3/6) ASCO 2017: STAMPEDE data

Dr Neal Shore, Prof Karim Fizazi, Prof Kurt Miller and Prof Nicholas James

(3/6) ASCO 2017: STAMPEDE data ( Dr Neal Shore, Prof Karim Fizazi, Prof Kurt Miller and Prof Nicholas James )

(4/6) ASCO 2017: Expert discussion on the latest in prostate cancer

Dr Neal Shore, Prof Karim Fizazi, Prof Kurt Miller and Prof Nicholas James

(4/6) ASCO 2017: Expert discussion on the latest in prostate cancer ( Dr Neal Shore, Prof Karim Fizazi, Prof Kurt Miller and Prof Nicholas James )

(5/6) ASCO 2017: ASCO highlights in prostate cancer

Dr Neal Shore, Prof Karim Fizazi, Prof Kurt Miller and Prof Nicholas James

(5/6) ASCO 2017: ASCO highlights in prostate cancer ( Dr Neal Shore, Prof Karim Fizazi, Prof Kurt Miller and Prof Nicholas James )

(6/6) ASCO 2017: Round up of expert discussion on the latest in prostate cancer

Dr Neal Shore, Prof Karim Fizazi, Prof Kurt Miller and Prof Nicholas James

(6/6) ASCO 2017: Round up of expert discussion on the latest in prostate cancer ( Dr Neal Shore, Prof Karim Fizazi, Prof Kurt Miller and Prof Nicholas James )

Clinical potential of trastuzumab biosimilar CTP6

Prof Francisco Esteva - NYU Langone Medical Center, New York, USA

Clinical potential of trastuzumab biosimilar CTP6 ( Prof Francisco Esteva - NYU Langone Medical Center, New York, USA )

ASCO 2017: Round up

Dr Bishal Gyawali - Nagoya University, Nagoya, Japan

ASCO 2017: Round up ( Dr Bishal Gyawali - Nagoya University, Nagoya, Japan )

Updates in melanoma: Treating BRAF and brain metastases

Prof Georgina Long - University of Sydney, Sydney, Australia

Updates in melanoma: Treating BRAF and brain metastases ( Prof Georgina Long - University of Sydney, Sydney, Australia )

Bendamustine for indolent lymphoma reduces relapse after 10 years

Dr Mathias Rummel - University of Giessen, Giessen, Germany

Bendamustine for indolent lymphoma reduces relapse after 10 years ( Dr Mathias Rummel - University of Giessen, Giessen, Germany )

ShortHER trastuzumab treatment of HER2 breast cancer: 9 weeks v 1 year

Prof Pierfranco Conte - Istituto Oncologico Veneto, Padova, Italy

ShortHER trastuzumab treatment of HER2 breast cancer: 9 weeks v 1 year ( Prof Pierfranco Conte - Istituto Oncologico Veneto, Padova, Italy )

T-VEC and checkpoint therapy for melanoma

Prof Robert Andtbacka - Huntsman Cancer Institute, Salt Lake City, USA

T-VEC and checkpoint therapy for melanoma ( Prof Robert Andtbacka - Huntsman Cancer Institute, Salt Lake City, USA )

Prevalence of homologous recombination deficiency among 53,000 tumour samples

Dr Arielle Heeke - Georgetown Lombardi Comprehensive Cancer Center, Washington, ...

Prevalence of homologous recombination deficiency among 53,000 tumour samples ( Dr Arielle Heeke - Georgetown Lombardi Comprehensive Cancer Center, Washington, USA )

Natural plant based balm antidote to severe nail toxicity during chemotherapy

Dr Robert Thomas - Cambridge University Hospitals, Cambridge, UK

Natural plant based balm antidote to severe nail toxicity during chemotherapy ( Dr Robert Thomas - Cambridge University Hospitals, Cambridge, UK )

Dacomitinib for EGFR positive lung cancer

Dr Tony Mok, The Chinese University of Hong Kong, Shatin, China

Dacomitinib for EGFR positive lung cancer ( Dr Tony Mok, The Chinese University of Hong Kong, Shatin, China )

New ALK inhibitor alectinib halts lung cancer growth more than a year longer tha...

Dr Alice Shaw - Massachusetts General Hospital Cancer Center, Boston, USA

New ALK inhibitor alectinib halts lung cancer growth more than a year longer than crizotinib, with fewer severe side effects ( Dr Alice Shaw - Massachusetts General Hospital Cancer Center, Boston, USA )

ASCO 2017: Expert discussion on the latest in prostate cancer

Dr Neal Shore, Prof Karim Fizazi, Prof Kurt Miller and Prof Nicholas James

ASCO 2017: Expert discussion on the latest in prostate cancer ( Dr Neal Shore, Prof Karim Fizazi, Prof Kurt Miller and Prof Nicholas James )

ASCO 2017: Following the practice changing results from STAMPEDE

Dr Neal Shore and Prof Nicholas James

ASCO 2017: Following the practice changing results from STAMPEDE ( Dr Neal Shore and Prof Nicholas James )

Treating advanced melanoma with ipilimumab and HF10

Prof Robert Andtbacka - Huntsman Cancer Institute, Salt Lake City, USA

Treating advanced melanoma with ipilimumab and HF10 ( Prof Robert Andtbacka - Huntsman Cancer Institute, Salt Lake City, USA )

Ado-trastuzumab emtansine in patients with HER2 mutant lung cancers

Dr Bob Li - Memorial Sloan Kettering Cancer Center, New York, USA

Ado-trastuzumab emtansine in patients with HER2 mutant lung cancers ( Dr Bob Li - Memorial Sloan Kettering Cancer Center, New York, USA )

Immunotherapy may slow the growth of malignant pleural mesothelioma

Dr Arnaud Scherpereel - University Hospital of Lille, Lille, France

Immunotherapy may slow the growth of malignant pleural mesothelioma ( Dr Arnaud Scherpereel - University Hospital of Lille, Lille, France )

Immunotherapy for mesothelioma could be on the horizon

Dr Arnaud Scherpereel - University Hospital of Lille, Lille, France

Immunotherapy for mesothelioma could be on the horizon ( Dr Arnaud Scherpereel - University Hospital of Lille, Lille, France )

CAR T-cell therapy can be used to send multiple myeloma into lasting remission

Dr Wanhong Zhao - Xi’an Jiaotong University Hospital, China

CAR T-cell therapy can be used to send multiple myeloma into lasting remission ( Dr Wanhong Zhao - Xi’an Jiaotong University Hospital, China )

Alectinib eclipses crizotinib for ALK positive lung cancer

Dr Alice Shaw - Massachusetts General Hospital Cancer Center, Boston, USA

Alectinib eclipses crizotinib for ALK positive lung cancer ( Dr Alice Shaw - Massachusetts General Hospital Cancer Center, Boston, USA )

Adding a second HER2 targeted medicine may lower chance of invasive breast cance...

Dr Gunter von Minckwitz - German Breast Group, Neu-Isenburg, Germany

Adding a second HER2 targeted medicine may lower chance of invasive breast cancer ( Dr Gunter von Minckwitz - German Breast Group, Neu-Isenburg, Germany )

Targeted sequencing in endocrine refractory breast cancer

Dr John Bartlett - Ontario Institute for Cancer Research, Toronto, Canada

$Targeted sequencing in endocrine refractory breast cancer ( Dr John Bartlett - Ontario Institute for Cancer Research, Toronto, Canada )$

Results from the APHINITY trial of two HER2 targeted agents with chemo

Prof Gunter von Minckwitz - German Breast Group, Neu-Isenburg, Germany

Results from the APHINITY trial of two HER2 targeted agents with chemo ( Prof Gunter von Minckwitz - German Breast Group, Neu-Isenburg, Germany )

Treating BRCA breast cancer with PARP inhibition

Dr Mika Sovak - AstraZeneca, Cambridge, UK

Treating BRCA breast cancer with PARP inhibition ( Dr Mika Sovak - AstraZeneca, Cambridge, UK )

Relieving spinal cord compression symptoms with a single radiation treatment

Prof Peter Hoskin - Mount Vernon Cancer Centre, Northwood, United Kingdom

Relieving spinal cord compression symptoms with a single radiation treatment ( Prof Peter Hoskin - Mount Vernon Cancer Centre, Northwood, United Kingdom )

Implementing new health initiatives in low-resource environments

Prof Sana Al Sakhun - Jordanian Oncology Society, Jordan

Implementing new health initiatives in low-resource environments ( Prof Sana Al Sakhun - Jordanian Oncology Society, Jordan )

Halving duration of ADT for high risk prostate cancer patients

Prof Abdenour Nabid - Sherbrooke University Hospital Centre, Sherbrooke, Canada

Halving duration of ADT for high risk prostate cancer patients ( Prof Abdenour Nabid - Sherbrooke University Hospital Centre, Sherbrooke, Canada )

New personalised therapies for lung cancer

Dr Luis Raez - Memorial Cancer Institute, Hollywood, Florida, USA

New personalised therapies for lung cancer ( Dr Luis Raez - Memorial Cancer Institute, Hollywood, Florida, USA )

Findings of a phase I/II study of nivolumab in patients with virus-associated tu...

Dr Antoine Hollebecque - Institut Gustave Roussy, Paris, France

Findings of a phase I/II study of nivolumab in patients with virus-associated tumours ( Dr Antoine Hollebecque - Institut Gustave Roussy, Paris, France )

Nivolumab and ipilimumab for metastatic sarcoma

Dr Sandra D'Angelo - Memorial Sloan Kettering Cancer Center, New York, USA

Nivolumab and ipilimumab for metastatic sarcoma ( Dr Sandra D'Angelo - Memorial Sloan Kettering Cancer Center, New York, USA )

Selumetinib in children with recurrent or refractory low-grade glioma

Dr Jason Fangusaro - Ann & Robert H. Lurie Children's Hospital of Chicago, Chica...

$Selumetinib in children with recurrent or refractory low-grade glioma ( Dr Jason Fangusaro - Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, USA )$

Dose escalation results of ceritinib and nivolumab for ALK NSCLC

Dr Enriqueta Felip - Vall d’Hebron University Hospital, Barcelona, Spain

Dose escalation results of ceritinib and nivolumab for ALK NSCLC ( Dr Enriqueta Felip - Vall d’Hebron University Hospital, Barcelona, Spain )

Phase III results of olaparib for BRCA breast cancer

Dr Mark Robson - Memorial Sloan Kettering Cancer Center, New York, USA

Phase III results of olaparib for BRCA breast cancer ( Dr Mark Robson - Memorial Sloan Kettering Cancer Center, New York, USA )

Global health initiative oncology

Prof Ophira Ginsburg - NYU Langone Medical Center, New York, USA

Global health initiative oncology ( Prof Ophira Ginsburg - NYU Langone Medical Center, New York, USA )

Self-reporting symptoms online improves patient care, chemotherapy duration and ...

Prof Ethan Basch - Lineberger Comprehensive Cancer Centre of the University of N...

Self-reporting symptoms online improves patient care, chemotherapy duration and survival ( Prof Ethan Basch - Lineberger Comprehensive Cancer Centre of the University of North Carolina, USA )

Tivantinib as second line therapy for high-MET HCC

Prof Lorenza Rimassa - Humanitas Cancer Center, Milan, Italy

Tivantinib as second line therapy for high-MET HCC ( Prof Lorenza Rimassa - Humanitas Cancer Center, Milan, Italy )

9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy

Prof Valentina Guarneri - Università degli Studi di Padova, Padua, Italy

9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy ( Prof Valentina Guarneri - Università degli Studi di Padova, Padua, Italy )

Expert prostate discussion: Clinical diagnostics, genomics, systemic and radiolo...

Dr Chris Parker and Prof Charles Ryan

Expert prostate discussion: Clinical diagnostics, genomics, systemic and radiological treatment ( Dr Chris Parker and Prof Charles Ryan )

Web-based system for self-reporting symptoms may help patients live longer

Prof Ethan Basch - Lineberger Comprehensive Cancer Centre of the University of N...

Web-based system for self-reporting symptoms may help patients live longer ( Prof Ethan Basch - Lineberger Comprehensive Cancer Centre of the University of North Carolina, USA )

Olaparib slows growth of BRCA-related metastatic breast cancer

Dr Mark Robson - Memorial Sloan Kettering Cancer Center, New York, USA

Olaparib slows growth of BRCA-related metastatic breast cancer ( Dr Mark Robson - Memorial Sloan Kettering Cancer Center, New York, USA )

Global study sets new risk-based standard to personalise chemotherapy for colon ...

Dr Axel Grothey - Mayo Clinic Cancer Centre, Rochester, USA

Global study sets new risk-based standard to personalise chemotherapy for colon cancer after surgery ( Dr Axel Grothey - Mayo Clinic Cancer Centre, Rochester, USA )

3 or 6 months adjuvant oxaliplatin for colorectal cancer

Dr Tim Iveson - University Hospital Southampton, Salisbury, UK

3 or 6 months adjuvant oxaliplatin for colorectal cancer ( Dr Tim Iveson - University Hospital Southampton, Salisbury, UK )

No link between pregnancy and breast cancer relapse

Dr Matteo Lambertini - Institut Jules Bordet, Brussels, Belgium

No link between pregnancy and breast cancer relapse ( Dr Matteo Lambertini - Institut Jules Bordet, Brussels, Belgium )

Cancer and caring in modern medicine

Prof Siddhartha Mukherjee - Columbia University Medical Center, New York, USA

Cancer and caring in modern medicine ( Prof Siddhartha Mukherjee - Columbia University Medical Center, New York, USA )

Pooled analysis of avelumab for metastatic urothelial carcinoma

Dr Andrea Apolo - National Cancer Institute, Bethesda, USA

Pooled analysis of avelumab for metastatic urothelial carcinoma ( Dr Andrea Apolo - National Cancer Institute, Bethesda, USA )

Cancer and living meaningfully: the CALM intervention

Dr Gary Rodin - Princess Margaret Cancer Centre, Toronto, Canada

Cancer and living meaningfully: the CALM intervention ( Dr Gary Rodin - Princess Margaret Cancer Centre, Toronto, Canada )

'Conquer Fear' of disease recurrence

Dr Jane Beith - University of Sydney, Sydney, Australia

'Conquer Fear' of disease recurrence ( Dr Jane Beith - University of Sydney, Sydney, Australia )

Screening for 508 genes in liquid biopsy to chart cancer evolution

Dr Pedram Razavi - Memorial Sloan Kettering Cancer Centre, New York, USA

Screening for 508 genes in liquid biopsy to chart cancer evolution ( Dr Pedram Razavi - Memorial Sloan Kettering Cancer Centre, New York, USA )

Larotrectinib shows durable efficacy across diverse paediatric and adult cancers

Dr David Hyman - Memorial Sloan Kettering Cancer Centre, New York, USA

Larotrectinib shows durable efficacy across diverse paediatric and adult cancers ( Dr David Hyman - Memorial Sloan Kettering Cancer Centre, New York, USA )

Routine genomic testing is feasible, but only a subset of patients benefit

Dr Olivier Trédan - Centre Léon Bérard, Lyon, France

Routine genomic testing is feasible, but only a subset of patients benefit ( Dr Olivier Trédan - Centre Léon Bérard, Lyon, France )

Molecular profiles and the future of adjuvant therapy

Dr Rodrigo Dienstmann - Vall d’Hebron Institute of Oncology, Barcelona, Spain

Molecular profiles and the future of adjuvant therapy ( Dr Rodrigo Dienstmann - Vall d’Hebron Institute of Oncology, Barcelona, Spain )

Pregnancy after breast cancer no associated with relapse risk

Dr Matteo Lambertini - Institut Jules Bordet, Brussels, Belgium

Pregnancy after breast cancer no associated with relapse risk ( Dr Matteo Lambertini - Institut Jules Bordet, Brussels, Belgium )

Delaying metastatic prostate cancer, improving survival with abiraterone

Prof Karim Fizazi - Institut Gustave Roussy, Paris, France

Delaying metastatic prostate cancer, improving survival with abiraterone ( Prof Karim Fizazi - Institut Gustave Roussy, Paris, France )

STAMPEDE trial: abiraterone for advanced prostate cancer reduces progression/dea...

Prof Nick James - Queen Elizabeth Hospital Birmingham & University of Birmingham...

STAMPEDE trial: abiraterone for advanced prostate cancer reduces progression/deaths ( Prof Nick James - Queen Elizabeth Hospital Birmingham & University of Birmingham, UK )

Hypogonadism following cisplatin treatment of testicular cancer

Dr Mohammad Issam Abu Zaid - Indiana University School of Medicine, Indianapolis...

Hypogonadism following cisplatin treatment of testicular cancer ( Dr Mohammad Issam Abu Zaid - Indiana University School of Medicine, Indianapolis, USA )

Recent childhood cancer survivors face less chronic disease risk than previous d...

Dr Todd Gibson - St Jude Children's Research Hospital, Memphis, USA

Recent childhood cancer survivors face less chronic disease risk than previous decades ( Dr Todd Gibson - St Jude Children's Research Hospital, Memphis, USA )

Steady decrease in severe health problems for childhood cancer survivors

Dr Todd M. Gibson - St Jude Children's Research Hospital, Memphis, USA

Steady decrease in severe health problems for childhood cancer survivors ( Dr Todd M. Gibson - St Jude Children's Research Hospital, Memphis, USA )

Low testosterone after testicular cancer could be linked to chronic health probl...

Dr Mohammad Issam Abu Zaid - Indiana University School of Medicine, Indianapolis...

Low testosterone after testicular cancer could be linked to chronic health problems ( Dr Mohammad Issam Abu Zaid - Indiana University School of Medicine, Indianapolis, USA )

Single radiation treatment can sufficiently relieve spinal cord compression symp...

Prof Peter Hoskin - Mount Vernon Cancer Centre, Northwood, United Kingdom

Single radiation treatment can sufficiently relieve spinal cord compression symptoms ( Prof Peter Hoskin - Mount Vernon Cancer Centre, Northwood, United Kingdom )

Web-based remote therapy program improves quality of life and lowers distress af...

Dr Viviane Hess - University Hospital of Basel, Basel, Switzerland

Web-based remote therapy program improves quality of life and lowers distress after diagnosis ( Dr Viviane Hess - University Hospital of Basel, Basel, Switzerland )

Easing distress in patients with cognitive therapy

Dr Gary Rodin - Princess Margaret Cancer Centre, Toronto, Canada

Easing distress in patients with cognitive therapy ( Dr Gary Rodin - Princess Margaret Cancer Centre, Toronto, Canada )

Psychological intervention lowers fear of cancer recurrence

Dr Jane Beith - University of Sydney, Australia

Psychological intervention lowers fear of cancer recurrence ( Dr Jane Beith - University of Sydney, Australia )

More from ecancer